On August 29, 2025, the Guangdong-Macao In-Depth Cooperation Zone In Hengqin Enterprise High-Quality Development Conference and the launching ceremony of the “Seedling Cultivation and Excellence Promotion” program were successfully held. Beletalent (Zhuhai) Pharmaceutical Co., Ltd. (hereinafter referred to as “Beletalent”) successfully made it into the first batch of “Seedling Cultivation Enterprises” in the Cooperation Zone. As a wholly-owned subsidiary of Guizhou Bailing Enterprise Group, Beletalent will take this opportunity to deepen innovative research and development of traditional Chinese medicine (TCM) and cross-border industrial layout, contributing to the high-quality development of the In-Depth Cooperation Zone pharmaceutical industry.
Rooted in Hengqin, Building the Foundation for “Seedling Cultivation” with Innovative R&D
Founded in 2023 with a registered capital of 20 million yuan, Beletalent is a headquarters for innovative TCM R&D in Hengqin and Macao’s TCM overseas trade, jointly established by Guizhou Bailing’s National Enterprise Technology Center and National and Local Engineering Research Center. Leveraging the Guangdong-Macao In-Depth Cooperation Zone in Hengqin’s geographical advantage as a new demonstration zone for the “One Country, Two Systems” practice, the company specializes in original innovative drug R&D, industrialization, and domestic and overseas pharmaceutical product sales. It has built a distinctive pharmaceutical R&D pipeline covering Class 1 innovative drugs, Class 1.2 improved new drugs, generic drugs with the same name, and product registrations in Portuguese-speaking countries, among which 1 project has entered Phase III clinical trials.
Backed by Guizhou Bailing Group’s technological accumulation and a first-class expert team, Beletalent currently has nearly 50 employees and 27 core technical personnel, among whom 9 hold senior professional titles or doctoral degrees, providing solid support for innovative research. Notably, its core product, Tangning Tongluo Tablets, has benefited from the Cooperation Zone’s policy dividends. It is the first Class 1.1 TCM innovative drug to be exempted from Phase I and II clinical trials based on human use experience under the Special Regulations on the Administration of Traditional Chinese Medicine Registration, significantly shortening the R&D cycle and accelerating its availability to global diabetes patients.
Aligning with “Four New” Industries, Growing with the Cooperation Zone
The “Seedling Cultivation and Excellence Promotion” program focuses on fostering the Cooperation Zone’s “four new” industries (new technologies, new industries, new formats, new models) and supports enterprise growth through “gradient and full-cycle” services. Beletalent’s development path highly aligns with the program’s philosophy: on one hand, it deeply engages in TCM innovative drug R&D, oriented toward addressing major clinical needs and enhancing technological innovation capabilities; on the other hand, it fully leverages Hengqin’s geographical advantage as a link between Hong Kong, Macao, and Portuguese-speaking countries, expanding international markets through cross-border e-commerce. It aims to gradually build a CDMO (Contract Development and Manufacturing Organization) + CSO (Contract Sales Organization) industrial ecosystem for TCM in Hengqin, serving the health needs of residents in Qin-Ao while promoting TCM to the world.
A responsible person from Beletalent stated, “Being selected as a ‘Seedling Cultivation Enterprise’ recognizes our R&D strength and development potential, strengthening our confidence in rooting in Hengqin and deepening TCM innovation. The Cooperation Zone’s ‘full-cycle butler-style services’ provide fertile ground for enterprises. Going forward, we will accelerate the implementation of clinical projects, deepen pharmaceutical trade cooperation with Macao and Portuguese-speaking countries, and strive to move from ‘seedling cultivation’ to ‘excellence cultivation’ as soon as possible, contributing to In-Depth Cooperation Zone’s industrial upgrading.”
Future Outlook: Practicing the Mission of “TCM Going Global” with Action
According to the “Seedling Cultivation and Excellence Promotion” program, the Cooperation Zone will help enterprises in the database achieve both scale and capability upgrading through dynamic cultivation. Beletalent plans to expand its R&D team, accelerate the market launch of core products such as Tangning Tongluo Tablets, and promote more TCM innovative drugs to complete registration in Macao and international markets with policy support.
As a rising force in TCM innovation in Hengqin, Beletalent will take this selection as a starting point, continuing to practice its mission of “empowering TCM with technology and innovating to serve the world.” It will thrive in the “vibrant soil” of the Cooperation Zone, contributing to the high-quality development of the Greater Bay Area’s pharmaceutical industry and the new demonstration of “One Country, Two Systems” practice.
【About Beletalent (Zhuhai) Pharmaceutical Co., Ltd.】
Beletalent is a wholly-owned subsidiary of Guizhou Bailing Enterprise Group Pharmaceutical Co., Ltd., a top 100 listed pharmaceutical company in China. It specializes in original innovative drug R&D, industrialization, and domestic and overseas pharmaceutical product sales, aiming to become a benchmark enterprise for TCM innovative R&D and overseas trade based in the Guangdong-Macao In-Depth Cooperation Zone in Hengqin.
